LifeVantage (NASDAQ:LFVN) Posts Quarterly Earnings Results

LifeVantage (NASDAQ:LFVN) announced its quarterly earnings data on Wednesday. The company reported $0.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.08, Zacks reports. LifeVantage had a return on equity of 29.24% and a net margin of 2.11%.

LifeVantage Stock Performance

Shares of LifeVantage stock traded down $1.00 during midday trading on Wednesday, hitting $22.74. 486,894 shares of the company traded hands, compared to its average volume of 270,076. The stock has a market cap of $284.70 million, a price-to-earnings ratio of 71.06 and a beta of 0.84. The firm’s fifty day moving average price is $18.97 and its 200-day moving average price is $13.59. LifeVantage has a 12 month low of $5.22 and a 12 month high of $27.38.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LFVN. Craig Hallum initiated coverage on shares of LifeVantage in a research note on Tuesday, January 14th. They set a “buy” rating and a $35.00 price objective on the stock. Lake Street Capital initiated coverage on LifeVantage in a research note on Thursday, December 19th. They issued a “buy” rating and a $26.00 price target for the company.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.